← Leaderboards
Brian Agnew
Sloan-Kettering Inst Can Research
$676,696
Attributed
$2,706,782
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $685.2K · FY2016–19$1M$750K$500K$250K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$2,706,782 · 1
By mechanism
R01$2,706,782 · 1
Top collaborators
- Jason S Lewis4 shared
- Gary Allan Ulaner4 shared
- Brian Matthew Zeglis4 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jason S Lewis$26,024,327
- Brian Matthew Zeglis$6,881,872
- John Thomas Poirier$4,490,380
- Mark P. Dunphy$3,061,237
- Jennifer Lynn Stockdill$2,139,411
Others in their field
Top investigators on “Erbb2 Gene”
- Norman Wolmark · Nsabp Foundation, Inc.$43,988,954
- Charles M Perou · Univ Of North Carolina Chapel Hill$10,910,346
- Ellen M Velie · Michigan State University$10,395,017
- Leslie Bernstein · University Of Southern California$10,393,428
- Lewis A Chodosh · University Of Pennsylvania$10,338,684
- Carlos L Arteaga · Vanderbilt University$9,797,101
Research focus
Erbb2 GeneImageDiscipline Of Nuclear MedicineAcuteAminesExhibitsBaseAntibodiesBiodistributionAntibody ConjugateAntigen Antibody BindingCancer CareAwardChelating AgentsClinicClinical CareBehaviorClinical TrialsCollaborationsColorectal CancerCouplingDeferoxamineDesignImaging Agent
Grant awards (4)
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$679,482
R01 · FY2019 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$674,466
R01 · FY2018 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$667,617
R01 · FY2017 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$685,217
R01 · FY2016 · CA